Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader Thermo Fisher Scientific (NYSE: TMO) to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) aimed at enhancing precision cancer therapies. Financial terms of the collaboration remain undisclosed.
According to the press release, the diagnostic tests will leverage Thermo Fisher’s advanced NGS platform, capable of analyzing tumor or liquid biopsy samples with a remarkable turnaround time of just 24 hours. The rapid results are expected to facilitate the matching of patients to Bayer’s precision oncology portfolio, thereby optimizing treatment pathways.- Flcube.com
